Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

98 per diluted common share, and $14.7 million, or $1.51 per diluted common share, respectively. The net loss in the years ended December 31, 2012 and 2011 included a non-cash gain on revaluation of our warrant liability of $4.5 million and $7.4 million, respectively. 
  • We had $75.4 million in cash, cash equivalents and short-term investments as of December 31, 2012, compared to $64.9 million as of December 31, 2011.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 million to $50 million.
  • Year-end cash, cash equivalents and investments are expected to be in the range of $25 million to $35 million.
  • Based on our current expectations, we believe our capital resources as of December 31, 2012 will be sufficient to fund our currently planned operations into 2015.
  • At March 7, 2013, we had 14,658,766 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended December 31,Year ended December 31,2012201120122011Collaboration revenue$
    9,780$
    ,236$
    20,095$
    5,496Operating expenses:  Research and development15,6457,47739,94821,553  General and administrative2,0421,7317,7916,230  Restructuring gain(1,657)-(1,657)-Total operating expenses16,0309,20846,08227,783Loss from operations6,2507,97225,98722,287  Other income (expense)2,147(1,596)4,8897,614Loss for the period before income taxes(4,103)(9,568)(21,098)(14,673)  Income taxes----Net loss$
    (4,103)$
    (9,568)$   (21,098)$ (14,673)Basic and diluted net loss per share$
    (0.28)$
    (0.98)$
    (1.56)$
    (1.51)Weighted average number of basic and diluted common shares14,656,7939,748,63913,522,7239,729,340Consolidated Balance Sheets(In thousands) December 31,  December 31, 20122011 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
    75,697$
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), the ... for a 2015 Connected World magazine Connected ... System (mPERS), that can be used anywhere, anytime. The ... In nominating MedScope, Landon Garner ...
    (Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
    (Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
    Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
    ... Denali Concrete Management Inc. (OTCBB: DCMG) announced today ... acquisition of Denali by Can-Fite BioPharma Ltd. (TASE: CFBI) ... outstanding shares of EyeFite Ltd., a private company incorporated ... exclusive license over CF101 for ophthalmic indications. Concurrently, Denali ...
    ... 22, 2011 Par Pharmaceutical Companies, Inc. (NYSE: ... approved the promotions of Thomas J. Haughey to the role ... Chief Operating Officer of the Company and its subsidiaries, effective ... LePore who will retain his title of Chairman of the ...
    Cached Medicine Technology:Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer 2
    (Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
    (Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
    (Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
    (Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
    Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
    ... , , , OAKLAND, Calif., ... host a Breema Intensive on February 6-14, 2010. The Intensive program ... to help advanced students deepen their practice of Breema and its ... Oakland, California. Participants can choose from a 2-day, 3-day or 6-day ...
    ... ... the more than 200 available models can be a daunting task. To ease the ... a series of eBooks on electric mobility scooters. Don’t get stuck in the mud ... ...
    ... ... rehab based in Texas, announced today that it has expanded its’ continuum of care with ... ... Origins Recovery, LLC announced today that it has expanded its’ continuum of care to include ...
    ... 28 The Providence Service Corporation (Nasdaq: PRSC ) ... last week by the United States Senate. The Senate ... Bill and therefore could still undergo substantial changes, has a ... many of the types of home and community based social ...
    ... have created what appears to be a schizophrenic mouse ... complex reasoning and decisions about appropriate social behavior. ... 28 in PNAS, elucidate the critical balance between excitation ... awry in schizophrenia. They also provide the first animal ...
    ... , NEW YORK, Dec. 28 The Michael J. ... $2 million to five research teams carrying out clinical studies ... in Parkinson,s disease, and help speed the development of urgently ... lead gift from The Edmond J. Safra Foundation, a steadfast ...
    Cached Medicine News:Health News:The Breema Center Announces Its Winter Intensive 2Health News:The Breema Center Announces Its Winter Intensive 3Health News:Will Your Purchase of an Electric Mobility Scooter Lead to a Comedy of Errors? 2Health News:Will Your Purchase of an Electric Mobility Scooter Lead to a Comedy of Errors? 3Health News:Will Your Purchase of an Electric Mobility Scooter Lead to a Comedy of Errors? 4Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 2Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 3Health News:Providence Service Corporation Comments on Senate Health Care Reform 2Health News:Providence Service Corporation Comments on Senate Health Care Reform 3Health News:Schizophrenia mouse model should improve understanding and treatment of the disorder 2Health News:Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinson's Disease 2Health News:Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinson's Disease 3
    Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
    ... supplied on Smart Cards. Insert the card and ... and turns itself off after the programmed time. ... duration of treatments. Simply provide your patient with ... their progress on the next visit.,The initial set ...
    ... painfree therapy stimulates the spincter and ... contractions and relaxation. By use of ... surgical operations (bladder liftings) may be ... can improve unsatisfying results. DETRUSAM intravesical ...
    ... ELPHA 4 Conti is a battery operated ... treatment of conditions described below. ELPHA 4 Conti ... In STRESS- and faecal incontinence ELPHA 4 Conti ... that the user can feel which muscles need ...
    Medicine Products: